表紙
市場調査レポート

Kareus Therapeutics, SA の製品パイプライン分析

Kareus Therapeutics, SA - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 319982
出版日 ページ情報 英文 22 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
Kareus Therapeutics, SA の製品パイプライン分析 Kareus Therapeutics, SA - Product Pipeline Review - 2015
出版日: 2015年12月16日 ページ情報: 英文 22 Pages
概要

Kareus Therapeutics, SA はスイスに本社をもつバイオテクノロジー企業で、加齢性疾患や慢性疾患を対象に低分子医薬品の創薬および開発を行っています。パイプライン製品にはインスリン増感剤や、アルツハイマー病、心疾患、代謝系疾患、炎症疾患の治療薬などがあり、他の製薬企業との提携下で開発が行われています。

当レポートでは、Kareus Therapeutics, SA における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Kareus Therapeutics, SA の基本情報

  • Kareus Therapeutics, SA の概要
  • 主要情報
  • 企業情報

Kareus Therapeutics, SA :R&Dの概要

  • 主な治療範囲

Kareus Therapeutics, SA :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Kareus Therapeutics, SA :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第1段階の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Kareus Therapeutics, SA :薬剤プロファイル

  • KU-046
  • KU-5039
  • Small Molecule for Cancer
  • Small Molecule for Neuropathic Pain and Inflammatory Pain

Kareus Therapeutics, SA :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Kareus Therapeutics, SA :最近のパイプライン情報

Kareus Therapeutics, SA :開発が休止されたプロジェクト

Kareus Therapeutics, SA :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07877CDB

Summary

Global Markets Direct's, 'Kareus Therapeutics, SA - Product Pipeline Review - 2015', provides an overview of the Kareus Therapeutics, SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Kareus Therapeutics, SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Kareus Therapeutics, SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Kareus Therapeutics, SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Kareus Therapeutics, SA's pipeline products

Reasons to buy

  • Evaluate Kareus Therapeutics, SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Kareus Therapeutics, SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Kareus Therapeutics, SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Kareus Therapeutics, SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kareus Therapeutics, SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Kareus Therapeutics, SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Kareus Therapeutics, SA Snapshot
    • Kareus Therapeutics, SA Overview
    • Key Information
    • Key Facts
  • Kareus Therapeutics, SA - Research and Development Overview
    • Key Therapeutic Areas
  • Kareus Therapeutics, SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Kareus Therapeutics, SA - Pipeline Products Glance
    • Kareus Therapeutics, SA - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Kareus Therapeutics, SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Kareus Therapeutics, SA - Drug Profiles
    • KU-046
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KU-5039
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Neuropathic Pain and Inflammatory Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Kareus Therapeutics, SA - Pipeline Analysis
    • Kareus Therapeutics, SA - Pipeline Products by Target
    • Kareus Therapeutics, SA - Pipeline Products by Route of Administration
    • Kareus Therapeutics, SA - Pipeline Products by Molecule Type
    • Kareus Therapeutics, SA - Pipeline Products by Mechanism of Action
  • Kareus Therapeutics, SA - Recent Pipeline Updates
  • Kareus Therapeutics, SA - Dormant Projects
  • Kareus Therapeutics, SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Kareus Therapeutics, SA, Key Information
  • Kareus Therapeutics, SA, Key Facts
  • Kareus Therapeutics, SA - Pipeline by Indication, 2015
  • Kareus Therapeutics, SA - Pipeline by Stage of Development, 2015
  • Kareus Therapeutics, SA - Monotherapy Products in Pipeline, 2015
  • Kareus Therapeutics, SA - Phase I, 2015
  • Kareus Therapeutics, SA - Preclinical, 2015
  • Kareus Therapeutics, SA - Pipeline by Target, 2015
  • Kareus Therapeutics, SA - Pipeline by Route of Administration, 2015
  • Kareus Therapeutics, SA - Pipeline by Molecule Type, 2015
  • Kareus Therapeutics, SA - Pipeline Products by Mechanism of Action, 2015
  • Kareus Therapeutics, SA - Recent Pipeline Updates, 2015
  • Kareus Therapeutics, SA - Dormant Developmental Projects,2015

List of Figures

  • Kareus Therapeutics, SA - Pipeline by Top 10 Indication, 2015
  • Kareus Therapeutics, SA - Pipeline by Stage of Development, 2015
  • Kareus Therapeutics, SA - Monotherapy Products in Pipeline, 2015
  • Kareus Therapeutics, SA - Pipeline by Top 10 Target, 2015
  • Kareus Therapeutics, SA - Pipeline by Top 10 Route of Administration, 2015
  • Kareus Therapeutics, SA - Pipeline by Top 10 Molecule Type, 2015
  • Kareus Therapeutics, SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top